NewLink Genetics Corp
Change company Symbol lookup
Select an option...
NLNK NewLink Genetics Corp
SFDPF Spark Infrastructure Group
SEDO Seedo Corp
SBRKF Sparebank 1 SR Bank ASA
SBBZF Soilbuild Business Space REIT
SAVE Spirit Airlines Inc
SAPMY Saipem SpA
SAPMF Saipem SpA
SANM Sanmina Corp
SAFLY Safilo Group SpA
Go

Health Care : Biotechnology | Small Cap ValueCompany profile

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company's portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute Cellular Immunotherapy technology, which is designed to stimulate the human immune system to attack cancer cells. Its additional HyperAcute Cellular Immunotherapy product candidates in clinical development include tergenpumatucel-L and dorgenmeltucel-L for patients with advanced lung cancer and melanoma, respectively. Additionally, it has two small-molecule product candidates in clinical development: GDC-0919 and indoximod. These product candidates are indoleamine-2, 3-dioxygenase (IDO) pathway inhibitors and focus on breaking the immune system's tolerance to cancer.

Closing Price
$1.63
Day's Change
0.025 (1.56%)
Bid
--
Ask
--
B/A Size
--
Day's High
1.73
Day's Low
1.58
Volume
(Below Average)
Volume:
227,006

10-day average volume:
265,435
227,006

UPDATE: 'Terminator: Dark Fate' expected to lead weekend box office

9:15 am ET November 2, 2019 (MarketWatch)
Print

By Ciara Linnane, MarketWatch

Harriet Tubman biopic and Edward Norton-helmed 'Motherless Brooklyn' round out the weekend's new releases

"Terminator: Dark Fate," the latest installment in the franchise starring Arnold Schwarzenegger and Linda Hamilton, is expected to lead the U.S. box office this weekend, replacing "Maleficent: Mistress of Evil" and "Joker."

Box Office Mojo (https://www.boxofficemojo.com/article/ed3832546308/?ref_=bo_hm_hp)is expecting the film, the sixth in a now 35-year-old franchise, to rake in $38 million to $41 million in receipts, although industry estimates range as high as $47 million.

Still, the film, made by Viacom's (VIA) Paramount, is for now trending behind sci-fi rivals "Blade Runner 2049" and Star Trek "Beyond, as well as Terminator Genisys, the most recent installment of the franchise that was released in 2015, according to Box Office Mojo.

"Blade Runner 2049" (https://www.boxofficemojo.com/article/ed190841860/) took in $32.7 million in its opening weekend in 2017, while "Star Trek Beyond" (https://www.boxofficemojo.com/release/rl2960360961/?ref_=bo_at_a) grossed $59.2 million in 2016. The last Terminator film grossed a more modest $27 million in its opening weekend.

(https://www.youtube.com/watch?v=oxy8udgWRmo)

If the film succeeds in attaining the $47 million estimate, it would exceed the $44 million gross that "Terminator 3" grossed in its opening weekend back in 2003, making it the biggest domestic opening for a Terminator film.

The film has a 70% score from Rotten Tomatoes, (https://www.rottentomatoes.com/m/motherless_brooklyn) though the film-rating site's critics called it "a significant upgrade over its immediate predecessors, even if it lacks the thrilling firepower of the franchise's best installments."

See:'Joker,' the top-grossing R-rated movie ever, regains No. 1 spot at box office (http://www.marketwatch.com/story/joker-the-top-grossing-r-rated-movie-ever-regains-no-1-spot-at-box-office-2019-10-27)

The weekend will also see the release of "Harriet," a biopic of Harriet Tubman, the American abolitionist and political activist who is credited with helping about 70 people escape slavery using a network of safe houses known as the Underground Railroad. The film stars Cynthia Erivo in the starring role and is expected to take $7.5 million to $9.0 million in receipts in its opening weekend.

Read now:As Netflix earnings loom, here comes an onslaught of competition -- and content (http://www.marketwatch.com/story/as-netflix-earnings-nears-here-comes-an-onslaught-of-competition-and-content-2019-10-07)

"Harriet", made by Comcast's (CMCSA) Focus Features has a 73% score on Rotten Tomatoes.

See also:Spider-Man is sticking with the MCU after Sony and Disney swing a new deal (http://www.marketwatch.com/story/spider-man-is-sticking-with-the-mcu-after-sony-and-disney-swing-a-new-deal-2019-09-27)

Also coming this weekend is "Motherless Brooklyn," an adaptation of Jonathan Lethem's award-winning novel directed by and starring Edward Norton, along with Gugu Mbatha-Raw and Alec Baldwin. The film, which opens in just 1,332 theaters, is expected to garner about $2.5 million in receipts in its opening weekend. The film, made by Warner Bros. (T) has a 65% score on Rotten Tomatoes.

Read also: AMC Theatres launches streaming service in latest blow to Netflix (http://www.marketwatch.com/story/amc-theatres-launches-streaming-service-in-latest-blow-to-netflix-2019-10-15)

-Ciara Linnane; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

November 02, 2019 09:15 ET (13:15 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2019 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2019. All rights reserved.